Finn Stockinger
Equity Analyst & Investor, Technology Research
IQE still has plenty of upside as Tower Semiconductor's indium phosphide epitaxial wafer supplier for the NPO-to-CPO buildout. Tower said its multi-year epi wafer agreement with IQE leaves it extremely well positioned against the InP bottleneck. Tower's first NPO deployments come in 2027, with $1.3B of contract value for that year and higher numbers expected after, and it plans to quadruple Japanese silicon photonics capacity, with full readiness in Q4 2027. x.com x.com x.com
IQE's growth is driven by surging demand for its indium phosphide technology, essential to AI data-center optical photonics. H1 led it to raise full-year guidance to over 30% revenue growth, and aerospace and defense are also strong. It has over £41M of cash and zero bank debt after a dilutive raise cleared debt. Validation comes in 2027, when AI optical-interconnect demand should accelerate; if IQE becomes a key InP supplier, today's valuation could look very cheap. x.com x.com x.com x.com
IQE's new multi-year indium phosphide epiwafer supply deal with Tower Semiconductor puts a 5x-10x move from March 2026 levels in the works, and IQE is the pick over Tower itself. Per Wall St Engine, the wafers support Tower's silicon photonics platforms for AI data center optics, including 200G/lane pluggable transceivers, 400G/lane modulator prototypes and optical circuit switches. The two also settled their IP dispute, with Tower granting IQE a worldwide royalty-free license. x.com x.com
IQE's new multi-year InP epiwafer supply deal with Tower Semiconductor shows its product is irreplaceable, adding a third Tier-1 foundry anchor in the AI photonics stack after Lumentum and MACOM. IQE is the non-Chinese InP source Tower needed, a geopolitical moat, and is designed into the optical roadmap from 200G pluggables to 400G-per-lane modulators and optical circuit switches. Tower, which IQE sued for IP theft in 2022, even granted IQE a royalty-free patent license. x.com
IQE's bottleneck position in AI optics is already priced in, so the easy money is gone until its revenue and profits grow. Per @jpinsights, IQE grows the indium phosphide epiwafers high-speed lasers are built from, and validation came through MACOM's GBP45m investment, Tower's multi-year supply deal and a GBP81m raise. But the stock has rerated hard, and it is unclear whether any of this has reached IQE's own numbers. x.com
IQE is levered to whichever optical architecture wins: GaAs epiwafers if VCSELs gain ground, which seems likely, and indium phosphide epiwafers via Tower Semiconductor if silicon photonics wins. It built the world's largest VCSEL epiwafer facility in Newport and has automotive VCSEL volume orders plus growing defense demand. On June 15 it signed a multi-year InP supply deal with Tower for 200G/lane and 400G/lane products, settling their IP disputes. A small slice of either market would matter. … Show more
InP substrate demand and pricing still support the AI optics supply chain. Yunnan Germanium reports higher InP volumes from AI data centers and optical communications, plus higher prices. Q3 revenue rose 134.6% year on year, near AXT's guided 136%, but also includes germanium. IQE's H1 photonics grew 45%, partly from US defense funding. AXT's $66m Q3 guide covers only licensed exports or sales needing no license; a miss would more likely reflect licensing. x.com
IQE is hard to call undervalued because its price already embeds a mature-margin scenario two-plus years out. At a 15% margin and 20% yearly growth, FY28 EBITDA is about GBP25 million, worth about GBP500 million at a generous 20x, versus a GBP520 million market cap at 40p. IQE earns about 3% adjusted EBITDA margins versus LandMark's high-margin epi, MACOM's convertible and warrants carry about 76 million shares of overhang, and InP supply constraints threaten its H2-weighted guide. x.com x.com … Show more
Tower Semiconductor is building the foundry that silicon photonics needs, alongside its power management business, and its chart is flashing a blue buy signal again. x.com
IQE is reaching its financial inflection point as InP demand for AI and data centers drives growth. It raised 2026 revenue growth guidance from 20% to over 30% after H1 revenue of £64m versus £45m, and forecasts low-teens £m adjusted EBITDA. MACOM's investment left it debt-free with £42m of cash. The 30% target looks deliberately conservative after past over-optimism; as @mkfilko notes, it implies H2 revenue below H1, which seems unlikely. x.com x.com
IQE's outsourced epitaxy business is structurally disadvantaged because demanding optics customers want the whole chain under their own control. Big integrated players such as Lumentum and Applied Optoelectronics run their own reactors and want to control manufacturing conditions throughout. Shipping wafers to an outside fab for epi growth and back falls short of that ideal, so regardless of IQE's execution the business model is unappealing, even as @crux_capital_ turns more positive. x.com
Tower Semiconductor's 2028 guidance makes its shares attractively valued around $180 despite competition from Silith, GlobalFoundries, STMicroelectronics and others. The stock previously felt too rich to add to. x.com x.com
